Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
Breast CancerTo evaluate safety and efficacy of vismodegib with standard neoadjuvant chemotherapy in breast cancer patients based on the CTCAE v4 2010 To study changes in biomarkers involved in the Hedgehog (HH) pathway in the first biopsy as compared to the later one To detect predictive factors among patients who reached pathological complete response (pCR) as compared to those with no pCR To evaluate the role of the addition of vismodegib in the pCR rate To evaluate clinical responses by breast MRI and rates of breast conservative surgery after neoadjuvant chemotherapy To evaluate QOL with EORTC QLQ-C30 scale
A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases....
Breast CancerThe study is being conducted to assess the effectiveness and safety of treatment options for breast cancer brain metastases based on molecular typing.
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced...
Triple Negative Breast CancerNab-paclitaxelThis is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease. The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.
Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a...
Breast CancerThe purpose of this study is to evaluate the efficacy and safety of vinorelbine plus oxaliplatin in pretreated metastatic triple-negative breast cancer.
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast...
Triple Negative Breast Cancer (TNBC)The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treated after failure of standard therapy (including Anthracyclines and/or Taxanes).
Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast...
Advanced Solid TumorsTriple Negative Breast CancerThis is a first-in-human, phase I clinical research study with TT-00420, an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors. The study consists of a dose escalation part followed by a MTD expansion part.
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer...
Breast CancerBreast Diseases1 moreThis study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive...
Triple Negative Breast CancerEarly-stage Breast Cancer1 moreAn Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With...
Triple-negative Breast CancerThe purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR...
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast CancerThis study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative breast cancer, as well as the safety of treatment, at the same time, relevant exploratory biomarker research is conducted.